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ABSTRACT
Laboratory-based surveillance at a Finnish
paediatric tertiary-care centre during the period
1999–2006 identiﬁed 739 nosocomial bloodstream
infections (BSIs) (1.6 BSIs ⁄ 1000 patient-days).
High rates were detected among haematology
patients (4.9 BSIs ⁄ 1000 patient-days) and neona-
tology patients (3.2 BSIs ⁄ 1000 patient-days). Most
BSIs (95%) were primary infections, and 75% of
those were associated with a central line. The
most common pathogens were coagulase-nega-
tive staphylococci (52%), Staphylococcus aureus
(7%) and Candida species (6%). The overall
mortality rate within 7 days after the ﬁrst positive
blood culture was 3%. Those who died were more
likely to have been admitted to an intensive-care
unit or to have undergone surgery.
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Nosocomial bloodstream infections (BSIs) repre-
sent the most frequent type of healthcare-associ-
ated infection among paediatric patients [1–3]. The
clinical and epidemiological features of nosoco-
mial BSIs were evaluated, as well as the distribu-
tion and antimicrobial susceptibilities of the
causative pathogens during an 8-year study period
at the largest paediatric centre in Finland. Few
hospital-wide paediatric studies focusing on nos-
ocomial BSIs havebeenpublished todate [4–6], and
none of them was conducted in Europe.
The Hospital for Children and Adolescents,
Helsinki University Central Hospital, is a tertiary-
care paediatric centre with 15 000 annual admis-
sions. The hospital has a ten-bed paediatric
intensive-care unit and three high-risk nurseries.
Open-heart surgery and organ transplantation are
nationally centred in this hospital, serving a
population of 5.3 million. The data were collected
prospectively within the Finnish Hospital Infec-
tion Programme during the period 1999–2006, as
previously described [7], and CDC deﬁnitions
were used [8].
The hospital laboratory analysed blood cultures
via automated detection with Bact ⁄ALERT (Pae-
diatric PF bottles; BioMerieux, Marcy l’Etoile,
France) and identiﬁed the organisms according to
standard procedures [9]. The susceptibility tests
were performed by using antibiotic-containing
disks on Mueller–Hinton agar according to CLSI
protocols [10]. Both antibiotic-resistant and inter-
mediately susceptible organisms were considered
to be resistant when resistance rates were calcu-
lated. Categorical variables were analysed with
the chi-square test with Yates’ correction or
Fisher’s exact test, as appropriate, and continuous
variables with the Mann–Whitney U-test.
In total, 833 nosocomial BSIs were identiﬁed in
694 patients. The study excluded neonatal BSIs
with onsets during the ﬁrst 72 h of life, and thus
739 nosocomial BSIs in 600 patients were included
in the analysis (overall rate, 5.7 ⁄ 1000 discharges)
(Table 1). The median age of the patients was
48 days; 53% of them were male. The most
common underlying factors were intensive-care
unit stay (51%), newborn status (43%) and
surgery (26%). The BSI rates varied among
specialties (Table 1). Of the BSIs, 699 (95%) were
primary infections and 40 (5%) were secondary
infections. Central venous catheter (CVC) data
were available for 580 (83%) primary BSIs, and
75% of those were CVC-associated. In total,
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27 279 blood samples were obtained for culture
(median 62; range by year, 48–91 cultures per 1000
patient-days), and 27 BSIs were conﬁrmed per
1000 blood cultures (range by year, 18–36). No
association was found between the annual rates of
cultures performed and BSIs detected (Spear-
man’s correlation coefﬁcient 0.3, p 0.65).
In total, 825 isolates were recovered during the
739 BSI episodes, of which 77 (10%) were polymi-
crobial. The most common pathogens were
coagulase-negative staphylococci (CoNS), Staphy-
lococcus aureus and Candida species (Fig. 1). The
proportion of CoNS and Candida species was
higher in neonates than in other patients (p <0.01
for each comparison). Viridans group strepto-
cocci, Pseudomonas aeruginosa and Micrococcus,
Lactobacillus and Bacillus species were more fre-
quently seen in haematology patients (p <0.01),
and Klebsiella species were more frequently seen
in paediatric intensive-care unit patients
(p <0.01). The case-fatality rate within 7 days
after the positive blood culture was highest for
BSIs caused by Streptococcus agalactiae (one of six
patients, 17%), Enterobacter species (3 ⁄ 19, 16%),
Pseudomonas species (2 ⁄ 21, 10%) and Candida
species (4 ⁄ 47, 9%). The patients who died were
more likely to have been admitted to an intensive-
care unit (4% vs. 1%, p 0.02) or to have under-
gone surgery (5% vs. 2%, p 0.03).
Resistance to methicillin was detected in 86%
of the CoNS isolates, but in no S. aureus isolate.
No resistance to vancomycin was found in
Fig. 1. Distribution of the 825 noso-
comial bloodstream infection (BSI)
isolates within patient subpopula-
tions in the Hospital for Children
and Adolescents, Helsinki Univer-
sity Central Hospital, Finland, dur-
ing the period 1999–2006. PICU,
paediatric intensive care unit.
Table 1. Annual rates of nosocomial bloodstream infections (BSIs) within specialty units and hospital-wide during the
period 1999–2006 in the Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland
Unit
Number (rate, per 1000 patient-days) of BSIs
1999 2000 2001 2002 2003 2004 2005 2006 Overall
Haematology–oncology 28 (5.0) 44 (7.5) 37 (5.7) 18 (2.9) 23 (4.0) 28 (4.8) 28 (4.9) 21 (4.6) 227 (4.9)
Neonatologya 23 (2.8) 37 (2.5) 38 (2.8) 37 (2.5) 26 (1.8) 66 (4.9) 60 (4.4) 52 (3.6) 339 (3.2)
Paediatric intensive care 4 (1.6) 3 (1.1) 13 (5.0) 4 (1.7) 6 (2.2) 7 (2.5) 7 (2.6) 8 (3.0) 52 (2.5)
Other acute-care wards 18 (0.4) 13 (0.3) 16 (0.3) 18 (0.4) 13 (0.3) 24 (0.6) 7 (0.2) 12 (0.4) 121 (0.4)
Hospital-wide 73 (1.4) 97 (1.5) 104 (1.7) 77 (1.3) 68 (1.2) 125 (2.1) 102 (1.8) 93 (1.7) 739 (1.6)
aIncluding three units with 24 level II–III and 16 level I–II care beds in total. Approximately 150 very low birthweight (£1500 g) infants are admitted annually.
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either CoNS or enterococcal isolates. Of the
viridans group streptococcal isolates, 27% dis-
played resistance to penicillin, and 37% to
erythromycin. Of the Escherichia coli isolates,
51% were resistant to ampicillin, and >10% were
resistant to cefuroxime, ciproﬂoxacin and tobra-
mycin. All antimicrobials tested, except ampi-
cillin, were active against >90% of the Klebsiella
isolates. Of both the E. coli and Klebsiella isolates,
2% were resistant to ceftazidime (i.e. potential
producers of extended-spectrum b-lactamases).
Imipenem, ciproﬂoxacin and tobramycin were
highly active against Enterobacter species. Of
the P. aeruginosa isolates, 12% were resistant to
piperacillin–tazobactam or ceftazidime, and 6–7%
to imipenem or ciproﬂoxacin.
Nineteen (3%) patients died within 1 week
after the onset of the BSI; 18 ⁄ 19 patient charts
were available for review. In the majority of cases
(13 ⁄ 18), septicaemia was the cause of death. Ten
patients were newborns, and six of them were
born prematurely. Three patients had a haemato-
logical malignancy, and six exhibited a congenital
condition as an underlying factor. Fourteen
patients received appropriate empirical antimi-
crobial treatment after the clinical diagnosis of
BSI. Two patients had candidaemia and received
only antibacterial treatment, and one patient had
a BSI caused by cefuroxime-resistant Enterobacter
cloacae and was treated with cefuroxime only. One
patient who died without preceding symptoms
had received no empirical antimicrobial treat-
ment, and the diagnosis was only apparent
post mortem.
Reports on paediatric nosocomial BSIs have
often described outbreaks or focused on a partic-
ular pathogen or patient group [11–14]. A litera-
ture search yielded three hospital-wide reports
with CDC deﬁnitions: one multicentre report
from the USA [4], one from an Israeli tertiary-
care centre [6] and one from a Mexican general
hospital [5]. The rates of BSI and the attributable
mortality rates available from these studies varied
strongly (5.3 [6] and 29.4 [5] BSIs per 1000
discharges; mortality rates: 9% [6], 14% [4] and
38% [5]). Gram-negative pathogens predomi-
nated in two studies [5,6], and CoNS in one [4].
These differences can probably be explained by
the different hospital infrastructures, medical
practices and patient populations (e.g. exclusion
of patients <1 month of age [5]). Direct compar-
isons between the rates are likely to be misleading
also because the data were not adequately
adjusted for the patients’ risk factors. Unlike in
two of the other groups [4,6], no resistant strains
of S. aureus or Enterococcus faecium were found,
reﬂecting the resistance situation in Finland
(http://www.rivm.nl/earss/database).
In summary, CoNS were the most prevalent
causative agents of BSIs in this study, accounting
for 40% or more of the BSIs in each patient group
(Fig. 1). Most of the primary BSIs were CVC-
associated. As CVC use is a known risk factor for
BSIs [11,12], special attention should be given to
CVC care. At its best, BSI surveillance with
feedback is effective in reducing the incidence of
CVC-related BSIs [15,16]. It also offers the oppor-
tunity to gain up-to-date information on the most
likely pathogens and their antimicrobial resis-
tance patterns in different patient subpopulations,
and thus might help in the choice of empirical BSI
treatment.
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ABSTRACT
Using Streptococcus sinensis 16S rRNA-speciﬁc and
groEL gene-speciﬁc primers, a 128-bp fragment of
the 16S rRNA gene and a 433-bp fragment of the
groEL gene were ampliﬁed from bacterial DNA
recovered from 22 of 100 saliva samples from
healthy volunteers. There was no nucleotide
difference between the 88-bp 16S rRNA gene
fragments from the 22 saliva samples and that of
S. sinensis strain HKU4T, but there were zero to
eight nucleotide differences between the 311-bp
groEL gene fragments from the 22 samples and
that of S. sinensis strain HKU4T. The oral cavity is
the natural reservoir of S. sinensis.
Keywords 16S rRNA, groEL, oral cavity, reservoir,
Streptococcus sinensis
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In 2002, we reported the discovery of a novel
species of viridans streptococcus, Streptococcus
sinensis, isolated from multiple blood cultures of a
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